Takotsubo cardiomyopathy in Guillain-Barré syndrome
- PMID: 38573364
- DOI: 10.1007/s00415-024-12295-3
Takotsubo cardiomyopathy in Guillain-Barré syndrome
Abstract
Background and purpose: Takotsubo cardiomyopathy (TCM) is a serious autonomic complication of Guillain-Barré syndrome (GBS). However, the association between TCM and GBS has not been investigated in detail. We investigated the characteristics of GBS patients with TCM (GBS-TCM).
Methods: Clinical features and anti-ganglioside antibody between the GBS-TCM patients and 62 classical GBS patients without TCM as control patients were compared.
Results: Eight GBS-TCM patients were identified, in whom TCM was diagnosed at a mean of 6.5 [range 3-42] days after the onset of GBS. The age at onset of GBS was elder in the GBS-TCM patients than in the control GBS patients (76.5 [56-87] vs. 52 [20-88] years, p < 0.01). Notably, cranial nerve deficits, particularly in the lower cranial nerves, were observed in all GBS-TCM patients (100% vs. 41.9%, p < 0.01). Additionally, the GBS-TCM patients showed a higher GBS disability score at nadir (5 [4-5] vs. 4 [1-5], p < 0.01), and lower Medical Research Council sum scores at admission and nadir (37 [30-44] vs. 48 [12-60] at admission, p < 0.05, and 20 [12-44] vs. 40 [0-60] at nadir, p < 0.05, respectively). Mechanical ventilation was more frequently required in the GBS-TCM patients (62.5% vs. 11.3%, p < 0.01). Three GBS-TCM patients were positive for anti-ganglioside antibodies.
Conclusions: TCM occurred at a relatively early phase of GBS. The characteristics of GBS-TCM were the elder, lower cranial nerve involvements, severe limb weakness, and respiratory failure.
Keywords: Anti-ganglioside antibody; Cranial nerve deficits; Guillain–Barré syndrome; Mechanical ventilation; Takotsubo cardiomyopathy.
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
References
-
- Leonhard SE, Mandarakas MR, Gondim FAA et al (2019) Diagnosis and management of Guillain-Barré syndrome in ten steps. Nat Rev Neurol 15(11):671–683. https://doi.org/10.1038/s41582-019-0250-9 - DOI - PubMed - PMC
-
- van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, van Doorn PA (2014) Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol 10(8):469–482. https://doi.org/10.1038/nrneurol.2014.121 - DOI - PubMed
-
- Fokke C, van den Berg B, Drenthen J, Walgaard C, van Doorn PA, Jacobs BC (2014) Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain 137(Pt 1):33–43. https://doi.org/10.1093/brain/awt285 - DOI - PubMed
-
- Kusunoki S, Willison HJ, Jacobs BC (2021) Antiglycolipid antibodies in Guillain-Barré and Fisher syndromes: discovery, current status and future perspective. J Neurol Neurosurg Psychiatry 92(3):311–318. https://doi.org/10.1136/jnnp-2020-325053 - DOI - PubMed
-
- Sejvar JJ, Kohl KS, Gidudu J et al (2011) Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 29(3):599–612. https://doi.org/10.1016/j.vaccine.2010.06.003 - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical